Literature DB >> 23184095

Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.

Masato Yoneda1, Kento Imajo, Yuichiro Eguchi, Hideki Fujii, Yoshio Sumida, Hideyuki Hyogo, Masafumi Ono, Yasuaki Suzuki, Takumi Kawaguchi, Noriaki Aoki, Michio Sata, Kazuyuki Kanemasa, Yutaka Kohgo, Toshiji Saibara, Kazuaki Chayama, Yoshito Itoh, Toshikazu Yoshikawa, Keizo Anzai, Kazuma Fujimoto, Takeshi Okanoue, Atsushi Nakajima.   

Abstract

BACKGROUND: The severity of liver fibrosis must be estimated to determine the prognosis, for surveillance, and for optimal treatment of nonalcoholic fatty liver disease (NAFLD). However, the severity of hepatic fibrosis tends to be underestimated in patients with normal ALT.
METHODS: We investigated histological data and scoring systems (FIB-4 index, NAFLD fibrosis score, BARD score, and AST/ALT ratio) of 1,102 liver-biopsy-confirmed NAFLD patients.
RESULTS: A total of 235 NAFLD patients with normal ALT were estimated to exist. The ratio of advanced fibrosis (stage 3-4) was seen in 16.1 % of subjects with normal ALT. Scoring systems, especially the FIB-4 index and NAFLD fibrosis score, were clinically very useful (AUROC >0.8), even in patients with normal ALT. Furthermore, with resetting of the cutoff values, the FIB-4 index (>1.659) and NAFLD fibrosis score (>0.735) were found to have a higher sensitivity and higher specificity for the prediction of advanced fibrosis, and all of these scoring systems (FIB-4 index, NAFLD fibrosis score, BARD score, and AST/ALT ratio) had higher negative predictive values (>90.3 %). By using the resetting cutoff value, liver biopsy could have been avoided in 60.4 % (FIB-4), 66.4 % (NAFLD fibrosis score), 51.9 % (BARD score), and 62.1 % (AST/ALT ratio).
CONCLUSIONS: We reset the cutoff values of numerous non-invasive scoring systems to improve their clinical usefulness in the prediction of liver fibrosis in NAFLD patients with normal ALT, and these non-invasive scoring systems with the reset cutoff values could be of substantial benefit to reduce the number of liver biopsies performed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23184095     DOI: 10.1007/s00535-012-0704-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  42 in total

Review 1.  Appropriateness of liver biopsy.

Authors:  T Poynard; V Ratziu; P Bedossa
Journal:  Can J Gastroenterol       Date:  2000-06       Impact factor: 3.522

2.  Alanine aminotransferase levels: what's normal?

Authors:  Marshall M Kaplan
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

3.  Platelet count for predicting fibrosis in nonalcoholic fatty liver disease.

Authors:  Masato Yoneda; Hideki Fujii; Yoshio Sumida; Hideyuki Hyogo; Yoshito Itoh; Masafumi Ono; Yuichiro Eguchi; Yasuaki Suzuki; Noriaki Aoki; Kazuyuki Kanemasa; Kento Imajo; Kazuaki Chayama; Toshiji Saibara; Norifumi Kawada; Kazuma Fujimoto; Yutaka Kohgo; Toshikazu Yoshikawa; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2011-07-13       Impact factor: 7.527

Review 4.  Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography.

Authors:  Massimo Pinzani; Francesco Vizzutti; Umberto Arena; Fabio Marra
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-02

5.  Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography.

Authors:  Masato Yoneda; Kaori Suzuki; Shingo Kato; Koji Fujita; Yuichi Nozaki; Kunihiro Hosono; Satoru Saito; Atsushi Nakajima
Journal:  Radiology       Date:  2010-06-07       Impact factor: 11.105

6.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

7.  Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease.

Authors:  Raphael B Merriman; Linda D Ferrell; Marco G Patti; Shiobhan R Weston; Mark S Pabst; Bradley E Aouizerat; Nathan M Bass
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

8.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.

Authors:  Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

9.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Authors:  Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

10.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

Authors:  S A Harrison; D Oliver; H L Arnold; S Gogia; B A Neuschwander-Tetri
Journal:  Gut       Date:  2008-04-04       Impact factor: 23.059

View more
  16 in total

1.  Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.

Authors:  Takaomi Kessoku; Yuji Ogawa; Masato Yoneda; Kento Imajo; Yoshio Sumida; Yuichiro Eguchi; Hideki Fujii; Hideyuki Hyogo; Masafumi Ono; Yasuaki Suzuki; Takumi Kawaguchi; Kazuaki Chayama; Saiyu Tanaka; Kazuma Fujimoto; Keizo Anzai; Toshiji Saibara; Michio Sata; Yoshito Itoh; Atsushi Nakajima; Takeshi Okanoue
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

2.  Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer.

Authors:  Masashi Yahagi; Masashi Tsuruta; Hirotoshi Hasegawa; Koji Okabayashi; Yuko Kitagawa
Journal:  Mol Clin Oncol       Date:  2017-03-01

3.  FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients.

Authors:  Nozomi Kawata; Hirokazu Takahashi; Shinji Iwane; Kanako Inoue; Motoyasu Kojima; Michiko Kohno; Kenichi Tanaka; Hitoe Mori; Hiroshi Isoda; Satoshi Oeda; Yayoi Matsuda; Yoshiaki Egashira; Jyunichi Nojiri; Hiroyuki Irie; Yuichiro Eguchi; Keizo Anzai
Journal:  Diabetol Int       Date:  2020-07-09

Review 4.  Biomarkers in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Lawrence B Cohen; Radu M Nanau
Journal:  Can J Gastroenterol Hepatol       Date:  2014-12

Review 5.  Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.

Authors:  Kohei Oda; Hirofumi Uto; Seiichi Mawatari; Akio Ido
Journal:  Clin J Gastroenterol       Date:  2015-01-10

Review 6.  Treatment of rheumatoid arthritis with conventional, targeted and biological disease-modifying antirheumatic drugs in the setting of liver injury and non-alcoholic fatty liver disease.

Authors:  Tatjana Zekić; Mirjana Stanić Benić; Mislav Radić
Journal:  Rheumatol Int       Date:  2022-05-23       Impact factor: 3.580

7.  Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.

Authors:  Masataka Kanno; Kazunori Kawaguchi; Masao Honda; Rika Horii; Hajime Takatori; Tetsuro Shimakami; Kazuya Kitamura; Kuniaki Arai; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  J Gastroenterol       Date:  2019-02-01       Impact factor: 7.527

8.  Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis.

Authors:  Prashant Bafna; Rasmi Ranjan Sahoo; Kasturi Hazarika; Manesh Manoj; Sumit Rungta; Anupam Wakhlu
Journal:  Clin Rheumatol       Date:  2021-03-08       Impact factor: 2.980

9.  Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography.

Authors:  David J Harman; Stephen D Ryder; Martin W James; Matthew Jelpke; Dominic S Ottey; Emilie A Wilkes; Timothy R Card; Guruprasad P Aithal; Indra Neil Guha
Journal:  BMJ Open       Date:  2015-05-03       Impact factor: 2.692

10.  Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients.

Authors:  George Boon-Bee Goh; Mangesh R Pagadala; Jaividhya Dasarathy; Aynur Unalp-Arida; Ruth Sargent; Carol Hawkins; Achuthan Sourianarayanane; Amer Khiyami; Lisa Yerian; Rish K Pai; Srinivasan Dasarathy; Arthur J McCullough
Journal:  BBA Clin       Date:  2014-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.